Glioma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease (Astrocytoma, Oligoastrocytoma, Oligodendroglioma), By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Others), By Grade (Low Grade, High Grade), By End user (Hospital & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 9.34 Billion
CAGR (2026-2031)	7.95%
Fastest Growing Segment	Astrocytoma
Largest Market	North America
Market Size (2031)	USD 14.78 Billion

Market Overview

The Global Glioma Treatment Market will grow from USD 9.34 Billion in 2025 to USD 14.78 Billion by 2031 at a 7.95% CAGR. The Global Glioma Treatment Market encompasses therapeutic interventions for primary brain tumors originating from glial cells utilizing modalities such as surgical resection, radiation therapy, chemotherapy, and targeted immunotherapies. Growth in this sector is fundamentally driven by the rising geriatric population who exhibit a higher susceptibility to central nervous system malignancies alongside a general increase in the prevalence of these conditions globally. Furthermore, the expansion of healthcare infrastructure and superior diagnostic imaging technologies facilitate earlier detection and subsequent intervention thereby fueling the demand for established and novel therapeutic regimens.

According to the Central Brain Tumor Registry of the United States, in 2024, gliomas accounted for approximately 22.9% of all primary brain and other central nervous system tumors. Despite this significant disease burden, the market faces a substantial impediment regarding the blood-brain barrier which severely restricts the delivery of therapeutic agents to the tumor site. This physiological obstacle complicates the development of effective systemic treatments and frequently leads to high failure rates in clinical trials preventing rapid market expansion.

Key Market Drivers

The robust clinical pipeline of novel immunotherapies and targeted biologics is acting as a primary catalyst for market expansion. Pharmaceutical companies are increasingly focusing on IDH-mutant inhibitors to overcome resistance mechanisms. A pivotal development involves the regulatory success of targeted therapies that delay disease progression. According to Servier, August 2024, in the 'FDA Approves VORANIGO' press release, the Phase 3 INDIGO clinical trial demonstrated that vorasidenib reduced the risk of tumor progression or death by 61% in patients with Grade 2 IDH-mutant glioma compared to placebo. Such clinical milestones validate the efficacy of precision medicine and encourage further investment into expanding the therapeutic landscape.

Technological innovations in non-invasive modalities, particularly Tumor Treating Fields, are simultaneously altering treatment paradigms by extending survival rates. Developers are integrating these fields with standard radiotherapy to enhance local control. According to Novocure, May 2024, in the 'METIS Phase 3 Clinical Trial' announcement, patients treated with Tumor Treating Fields therapy exhibited a median time to intracranial progression of 21.9 months, significantly outperforming the 11.3 months observed in the control arm. These advancements are critical given the high mortality rates associated with these malignancies. According to the American Cancer Society, in 2024, approximately 18,760 individuals in the United States were projected to die from brain and other nervous system tumors, underscoring the need for these evolving interventions.

Download Free Sample Report

Key Market Challenges

The blood-brain barrier acts as a severe restriction on the Global Glioma Treatment Market by physically preventing therapeutic agents from reaching the tumor site. This physiological defense mechanism blocks the passage of most systemic drugs, which complicates drug formulation and necessitates expensive research efforts. Consequently, the development pipeline is fraught with obstacles that delay progress and inflate the cost of bringing new therapies to market.

This impediment directly stunts market growth by contributing to high attrition rates in clinical trials. The inability to demonstrate efficacy due to poor drug delivery results in a sparse commercial landscape, discouraging sustained financial investment. According to the National Brain Tumor Society, in 2024, there were only four FDA approved drugs available for the treatment of glioblastoma. This low number of marketable products limits revenue generation opportunities for industry players and highlights how the blood-brain barrier effectively bottlenecks the expansion of the sector by preventing the successful commercialization of novel treatments.

Key Market Trends

The Advancement of Chimeric Antigen Receptor (CAR) T-Cell Therapies is fundamentally reshaping the clinical landscape by addressing the challenge of solid tumor heterogeneity in glioblastoma. Researchers are now engineering T-cells capable of targeting multiple antigens simultaneously, such as EGFRvIII and wild-type EGFR, to prevent the antigen escape mechanisms that historically caused treatment failure. This shift from single-target to multi-target cellular engineering is yielding unprecedented responses in patients with recurrent disease. According to Massachusetts General Hospital, March 2024, in the 'Preliminary Clinical Trial Results Show Dramatic and Rapid Regression of Glioblastoma after Next Generation CAR-T Therapy' press release, patients treated with novel CAR-TEAM cells exhibited rapid responses, with one participant demonstrating a 60.7% decrease in tumor cross-sectional area by day 69. Such data indicates that cellular therapies are becoming a viable modality for central nervous system malignancies.

The Development of Novel Blood-Brain Barrier Crossing Delivery Systems is simultaneously overcoming the sector's most persistent physiological impediment. To enhance the efficacy of systemic cytotoxic agents, developers are validating implantable ultrasound technologies that temporarily disrupt the blood-brain barrier, allowing therapeutic concentrations of chemotherapy to reach the brain parenchyma. This approach effectively repurposes existing drugs that were previously limited by poor intracranial penetration. According to Carthera, March 2024, in the 'positive results from phase I/II clinical trial of SonoCloud-9' announcement, patients with recurrent glioblastoma who received carboplatin in combination with the device achieved a one-year overall survival rate of 58%, a substantial improvement over historical controls. This trend signifies a move toward device-drug combination strategies that maximize the utility of established pharmacotherapies.

Segmental Insights

The Astrocytoma segment is emerging as the fastest-growing category within the Global Glioma Treatment Market, fueled by the rising adoption of precision medicine. This expansion is principally driven by the development of novel therapeutics that address specific biomarkers, such as IDH mutations found in low-grade gliomas. A critical development reinforcing this growth is the recent approval by the U.S. Food and Drug Administration (FDA) of vorasidenib, the first targeted therapy for this indication. This regulatory milestone validates the efficacy of molecularly targeted treatments and significantly widens the available therapeutic options, thereby driving segmental momentum.

Regional Insights

North America holds a dominant position in the Global Glioma Treatment Market, driven by the high prevalence of central nervous system tumors and superior healthcare infrastructure. Reports from the American Society of Clinical Oncology highlight the significant incidence of primary brain tumors in the region, fueling the demand for effective therapies. The market is further propelled by the U.S. Food and Drug Administration (FDA), which supports innovation through expedited drug approvals and orphan drug designations. Additionally, the concentration of major pharmaceutical firms investing in extensive research and development activities secures the region's leading status.

Recent Developments

• In August 2024, Servier Pharmaceuticals significantly expanded the Global Glioma Treatment Market with the US FDA approval of vorasidenib, an oral, selective, and brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. Branded as Voranigo, this therapy became the first approved systemic treatment specifically for adult and pediatric patients with Grade 2 astrocytoma or oligodendroglioma exhibiting a susceptible IDH mutation following surgery. The regulatory approval was based on results from the Phase 3 INDIGO clinical trial, which showed a statistically significant improvement in progression-free survival and a delay in the time to the next intervention compared to placebo, offering a new standard of care for patients with diffuse low-grade gliomas.
• In July 2024, Kazia Therapeutics Limited provided an update relevant to the Global Glioma Treatment Market by announcing top-line results from the GBM-AGILE Phase 2/3 adaptive platform trial. The study evaluated the company's investigational drug, paxalisib, a PI3K/mTOR pathway inhibitor, against the standard of care in patients with glioblastoma. The company reported that the primary endpoint of overall survival was not met in the recurrent disease cohort, and the cumulative data did not reach statistical significance for the newly diagnosed cohort to proceed to the next stage. Despite the outcome, the completion of this study arm generated critical clinical data regarding the PI3K mechanism, informing future research directions in the treatment of resistant brain tumors.
• In May 2024, a notable development in the Global Glioma Treatment Market emerged through a strategic partnership between GSK and the Ivy Brain Tumor Center. The organizations announced the initiation of a global Phase 3 clinical trial, known as the Gliofocus Study, to evaluate the efficacy of niraparib, a selective PARP1/2 inhibitor, in adult patients with newly diagnosed MGMT-unmethylated glioblastoma. This randomized study was designed to compare the investigational drug against the standard-of-care chemotherapy, temozolomide, in patients who had also received radiation therapy. The collaboration highlights the industry's focus on accelerating the development of targeted therapies for aggressive brain malignancies by leveraging specialized translational research capabilities.
• In April 2024, Day One Biopharmaceuticals achieved a significant regulatory milestone in the Global Glioma Treatment Market with the US Food and Drug Administration (FDA) granting accelerated approval for its oral monotherapy, tovorafenib. Marketed under the brand name Ojemda, this type II RAF inhibitor is indicated for the treatment of patients aged six months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation. This decision marked the first systemic therapy approved specifically for patients with this genetic profile, addressing a critical unmet need in pediatric neuro-oncology. The approval was supported by data from the Phase 2 FIREFLY-1 clinical trial, which demonstrated meaningful overall response rates in the targeted patient population.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals LLC
• Merck & Co. KGaA
• Sun Pharmaceutical Industries Ltd
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Amneal Pharmaceuticals Inc
• Karyopharm Therapeutics Inc
• Biocon Ltd

By Disease	By Treatment Type	By Grade	By End user	By Region
Astrocytoma Oligoastrocytoma Oligodendroglioma	Surgery Chemotherapy Radiation Therapy Others	Low Grade High Grade	Hospital & Clinics Ambulatory Surgical Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Glioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Glioma Treatment Market, By Disease:

• Astrocytoma
• Oligoastrocytoma
• Oligodendroglioma

• Glioma Treatment Market, By Treatment Type:

• Surgery
• Chemotherapy
• Radiation Therapy
• Others

• Glioma Treatment Market, By Grade:

• Low Grade
• High Grade

• Glioma Treatment Market, By End user:

• Hospital & Clinics
• Ambulatory Surgical Centers
• Others

• Glioma Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE